Ligand Pharmaceuticals (LGND) net assets (shareholders' equity)

Net assets · fiscal 2025
$1.02B

Ligand Pharmaceuticals (LGND) had net assets of $1.02B at the end of fiscal 2025 (December 31, 2025). That is 22.5% higher than the $830.44M of fiscal 2024. Figures as of 19 Nov 2026, 00:03 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$1.02B
Change on fiscal 2024
+22.5%
Growth, 5 years
+7.5% a year
Growth, 10 years
+15.7% a year
Highest on record
$1.02Bfiscal 2025
Lowest on record
-$4.85Mfiscal 2010
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Ligand Pharmaceuticals net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 7.5% a year; over ten years the rate was 15.7% a year. Across the 17 fiscal years on record (2009–2025), the highest was $1.02B in fiscal 2025 and the lowest -$4.85M in fiscal 2010.

History · 17 fiscal years

Net assets by fiscal year

Ligand Pharmaceuticals net assets (shareholders' equity), year by year

Ligand Pharmaceuticals (LGND) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$1.02B 22.5% up
2024$830.44M 18.5% up
2023$700.91M 17.3% up
2022$597.49M 27.2% down
2021$821.16M 15.7% up
2020$709.53M 7.5% down
2019$767.23M 36.8% up
2018$560.91M 40.3% up
2017$399.79M 17.1% up
2016$341.29M 43.8% up
2015$237.28M 801.6% up
2014$26.32M 47.0% down
2013$49.61M 87.3% up
2012$26.49M 223.6% up
2011$8.19M—
2010-$4.85M 229.5% down
2009$3.74M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Ligand Pharmaceuticals and comparable companies
CompanyNet assetsFiscal year
RadNet RDNT$1.09B2025
Belite Bio BLTE$770.49M2025
Ligand Pharmaceuticals LGND$1.02B2025
Scholar Rock Holding SRRK$245.49M2025
Teleflex TFX$3.12B2025
Mirum Pharmaceuticals MIRM$314.69M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on LGND

Ligand Pharmaceuticals, figure by figure

Ligand Pharmaceuticals (LGND) overview: price, valuation and scorecardAll health care companies by market value

Ligand Pharmaceuticals net assets (shareholders' equity): questions and answers

What are Ligand Pharmaceuticals's net assets?

Ligand Pharmaceuticals (LGND) had net assets of $1.02B at the end of fiscal 2025 (December 31, 2025). That is 22.5% higher than the $830.44M of fiscal 2024.

What is the growth rate of Ligand Pharmaceuticals's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 7.5% a year; over ten years the rate was 15.7% a year.

What are the highest and lowest net assets figures on record for Ligand Pharmaceuticals?

Across the 17 fiscal years on record (2009–2025), the highest was $1.02B in fiscal 2025 and the lowest -$4.85M in fiscal 2010.

How is Ligand Pharmaceuticals's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Ligand Pharmaceuticals it is on record here for 17 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Ligand Pharmaceuticals (LGND) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/LGND/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.